Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Extends Delay In Returning Some OTCs To Market

This article was originally published in The Tan Sheet

Executive Summary

CFO Caruso says operating under a consent decree with “a third party in the manufacturing facilities with us” makes it “very difficult for us to predict exactly when products will return.” Some products will not return to stores until 2013, significantly later than the original goal to relaunch all recalled liquid OTCs before 2012.


Related Content

Promise Of A New Day For Rx-To-OTC Switch Ruled 2012 In “The Tan Sheet”
FDA Flags J&J For Inadequate Oversight Of Consumer Devices
McNeil Remediation Stretches Out, Dragging On J&J Consumer Sales
J&J CEO Choice Likely Will Not Raise Consumer Business Profile
McNeil Recalls Liquid Infants’ Tylenol With Dosing Device Problem
J&J’s Caruso Pitches OTC Comeback To Analysts
Neutrogena Enters Naturals Fray With Bio-Nutrient-Driven Skin Care
Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
Andrx Concerta


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts